AI
EBS icon

Axiom Investors’s Emergent Biosolutions EBS Stock Holding History

Axiom Investors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-44,251
Closed -$1.24M – 150
2016
Q2 		$1.24M Buy
+44,251
New +$1.73M 0.04% 130

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Axiom Investors's EBS Position: Q3 2016 in Review

Axiom Investors sold out of Emergent Biosolutions (EBS) in Q3 2016, closing a stake of 44,251 shares — an estimated $1.24M sold.

Axiom Investors first reported a position in EBS in Q2 2016 and held it in 1 quarter. The position peaked at $1.24M in Q2 2016. 203 funds tracked by Wall St. Rank hold EBS as of Q3 2016.

  • Axiom Investors reported no remaining Emergent Biosolutions position as of Q3 2016 after selling out during the quarter.
  • Axiom Investors sold 44,251 Emergent Biosolutions shares in Q3 2016, an estimated $1.24M.
  • Axiom Investors first reported a position in Emergent Biosolutions in Q2 2016 and held it in 1 quarter.
  • Axiom Investors's Emergent Biosolutions position peaked at $1.24M in Q2 2016.
  • 203 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2016.

Based on Axiom Investors's 13F filing for Q3 2016, filed 14 Nov 2016.